Tests extra heart ablation with standard treatment for paroxysmal atrial fibrillation
Tests extra heart ablation added to standard treatment in people with paroxysmal atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 75 with paroxysmal atrial fibrillation who have symptoms despite medicine and are willing to have a catheter ablation.
- Age
- 40 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Paroxysmal atrial fibrillation with symptoms that did not respond to one or more heart rhythm medicines.
- Earlier treatment
- Must not have had any earlier catheter ablation for a heart rhythm problem. Must not have had thoracic or heart surgery.
Main reasons for not taking part
- Earlier catheter ablation for heart rhythm problems
- Earlier chest or heart surgery
- History of cancer
- Permanent pacemaker
- Heart failure (ejection fraction 40% or less, or NYHA class III~IV)
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Source: NCT05908955, who can take part
Where in China
- Chinese Academy of Medical Science, Fuwai hospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT05908955
- Record updated
- 14 February 2025
- Original description
Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) has limited success. The superior vena cava (SVC) has been identified as one of the most common non-pulmonary vein triggers for PAF. It is estimated that SVC isolation (SVCI) could improve the clinical results for patients with PAF. However, results from previous studies about SVCI remain controversial. It is possible that safety concerns for SVCI outweigh its benefits and lead to inadequate ablation. To address this issue, the introduction of a quantitative ablation index (AI) for SVCI may provide a solution.Read full original descriptionShow less
Efficacy and Safety of Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: the SCORE Randomized Controlled Trial
Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) has limited success. The superior vena cava (SVC) has been identified as one of the most common non-pulmonary vein triggers for PAF. It is estimated that SVC isolation (SVCI) could improve the clinical results for patients with PAF. However, results from previous studies about SVCI remain controversial. It is possible that safety concerns for SVCI outweigh its benefits and lead to inadequate ablation. To address this issue, the introduction of a quantitative ablation index (AI) for SVCI may provide a solution.
The goal of this prospective, randomized controlled trial is to test the efficacy and safety of quantitative SVCI in addition to PVI in PAF. Participants with PAF will be randomly assigned to either PVI group or PVI+ quantitative SVCI group in a 1:1 ratio and will be followed up for 12 months. The main questions it aims to answer are:
1. Evaluate the efficacy of PVI+SVCI guided by quantitative AI. 2. Assess the safety of PVI+SVCI guided by quantitative AI.
The primary end point is treatment success at 3 months after the index ablation. The secondary end points include treatment success at 12 months, and safety outcomes.
Inclusion: Symptomatic paroxysmal AF that are unresponsive to antiarrhythmic drugs (one or more than one); Willing to undergo catheter ablation for AF; Age: 40-75 years old.
Exclusion: History of any type of catheter ablation for cardiac arrhythmias; History of any type of thoracic surgery, including cardiac surgery; History of malignant tumors; History of permanent pacemaker implantation; Allergy to contrast agents; Heart failure (left ventricular ejection fraction ≤40% or NYHA class III~IV); Age: <40yrs or >75yrs; Peripherally inserted central catheter for long-term; Sinus node dysfunction; Pregnancy or lactation.